2025年01月28日
2024.11.12
FRONTEO and Daiichi Sankyo signed an agreement for optimization and analysis of toxicity information with Drug Discovery AI Factory
Supporting the construction of innovative AI discovery systems to derive new findings from toxicity study database and toxicity study reports
FRONTEO, Inc. (Head Office: Minato-ku, Tokyo; President and CEO: Masahiro Morimoto; hereafter "FRONTEO") is pleased to announce that an agreement has been reached to provide Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and COO: Hiroyuki Okuzawa; hereafter "Daiichi Sankyo") with analysis services using Drug Discovery AI Factory (hereafter "DDAIF")* to analyze text information from toxicity study databases and reports.
Under this agreement, FRONTEO will develop referring function for toxicity interpretations in Daiichi Sankyo’s existing toxicity study database and an AI search system that enables the discovery of new findings and ideas through analysis of toxicity study reports.
* AI drug discovery support service that FRONTEO's drug discovery experts, who are well versed in AI and drug discovery, use the natural language processing technology of the specialized AI "KIBIT" developed in-house and the unique analysis methods to provide suggestions for target identification, drug repositioning, and the supporting hypotheses.
In this system, KIBIT will analyze text data from a vast volume of toxicity study reports that Daiichi Sankyo currently owns or will accumulate hereafter, as well as text data of academic papers published in PubMed. The system will also comprehensively present relationships between toxicity study reports that the researcher focuses on and conceptually similar papers or toxicity study reports in the form of a map and lists.
Based on the analysis results by KIBIT, researchers can identify relationships and trends in toxicity information that have not been previously assumed, enabling them to generate new hypotheses about mechanisms of toxicity. This is expected to lead to drug discovery and development that is not bound by preconceived ideas.
Figure: KIBIT converts papers and reports into vectors in several hundred dimensions, compresses them into two dimensions, and plots on a vector plane. Conceptually similar papers/reports are distributed nearby, allowing for a bird's-eye view of the relationships between information. This makes it possible to discover similarities and relationships among toxicity study reports and papers that would otherwise go undiscovered by conventional approaches.
KIBIT's strength is its unique technology for discovering new relationship not described in existing literature information. In recent years, although research on technologies and methodologies for efficiently accessing the information researchers seek from the vast amount of literature has advanced, making new discoveries from existing literature information still relies on researchers' own imagination and coincidence. FRONTEO has contributed to the innovative research and development of pharmaceutical companies by expanding DDAIF that uses KIBIT to enable the scientific and systematic discovery of relationships not described in existing literature information.
About FRONTEO URL: https://lifescience.fronteousa.com/
FRONTEO supports experts across various technological fields by providing valuable insights to jumpstart innovation through its proprietary specialized AI engine "KIBIT". KIBIT implements a unique natural language processing technology (patented in Japan and the United States) that enables high-speed and high-precision analysis of textual repositories without relying on large quantities of training data and computing power, unlike a general-purpose AI engine. By utilizing patented technology that visualizes the structure of relationships between analyzed information, KIBIT directly provides insights to experts that would otherwise be hidden. In recent years, KIBIT has also been incorporated into analysis tools used for hypothesis generation and target exploration in drug discovery.
In line with FRONTEO’s mission of supporting the information society by providing solutions that discover opportunities and risks that are otherwise hidden in documents, FRONTEO has leveraged KIBIT's unique technology in the fields of Life Science AI, Business Intelligence, Economic Security, and LegalTech AI, Founded in August 2003, listed on Tokyo Stock Exchange Mothers Market (now Tokyo Stock Exchange Growth Market) on June 26, 2007. The offices are located in Japan, the United States, South Korea, and Taiwan. Obtained the first-class marketing license for medical devices, registered controlled medical device sales business. Capital is 898,618,000 yen (as of August 31, 2024).
* FRONTEO, KIBIT and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.
Contact
Public Relations: pr_contact@fronteo.com
Life Science AI Business Division: https://lifescience.fronteousa.com/contact/
Do you have questions? We have answers.
FRONTEO eDiscovery experts are standing by to answer your questions about Artificial Intelligence and more.
FRONTEO, Shionogi, and Suzuken Collaborate to Implement Conversational Dementia Diagnosis Support AI Program in Society
May 13, 2024
UBE and FRONTEO launch co-creation project for drug repositioning using Drug Discovery AI Factory
November 14, 2024Related Posts
